Both Brand Lobbies Oppose Several Proposals In HHS Drug-Price Blueprint

By John Wilkerson / July 18, 2018 at 8:08 PM
The brand drug lobbies oppose several of the proposals in HHS' so-called blueprint for lowering drug prices, including proposals to change Part D coverage rules, apply Part D negotiation techniques to Part B, revive the Part B Competitive Acquisition Program, eliminate the Medicaid rebate cap and disclose list prices in drug ads. HHS Secretary Alex Azar said his top priority is moving Part B doctor-administered drugs into Part D where plans and pharmacy benefit managers negotiate prices. Both the Pharmaceutical...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.